Beijing Balance Medical Technology Co Ltd
Beijing Balance Medical Technology Co.,Ltd. engages in the research and development, production, sale, and service of animal-derived implantable medical devices in China. The company offers artificial biological heart valves, bovine pericardial and porcine aortic valves; pulmonary valved conduit; tissue antigen removal processor, annuloplasty and valvuloplasty rings, and surgical biological patch… Read more
Beijing Balance Medical Technology Co Ltd (688198) - Net Assets
Latest net assets as of June 2025: CN¥1.21 Billion CNY
Based on the latest financial reports, Beijing Balance Medical Technology Co Ltd (688198) has net assets worth CN¥1.21 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.45 Billion) and total liabilities (CN¥244.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.21 Billion |
| % of Total Assets | 83.22% |
| Annual Growth Rate | 38.22% |
| 5-Year Change | 49.62% |
| 10-Year Change | N/A |
| Growth Volatility | 90.53 |
Beijing Balance Medical Technology Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Beijing Balance Medical Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Balance Medical Technology Co Ltd (2016–2024)
The table below shows the annual net assets of Beijing Balance Medical Technology Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.25 Billion | +5.22% |
| 2023-12-31 | CN¥1.19 Billion | +8.10% |
| 2022-12-31 | CN¥1.10 Billion | +11.26% |
| 2021-12-31 | CN¥988.23 Million | +18.23% |
| 2020-12-31 | CN¥835.82 Million | +9.27% |
| 2019-12-31 | CN¥764.90 Million | +290.18% |
| 2018-12-31 | CN¥196.04 Million | +46.68% |
| 2017-12-31 | CN¥133.65 Million | +42.41% |
| 2016-12-31 | CN¥93.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Balance Medical Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 347.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥226.25 Million | 18.06% |
| Other Components | CN¥1.03 Billion | 81.94% |
| Total Equity | CN¥1.25 Billion | 100.00% |
Beijing Balance Medical Technology Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Balance Medical Technology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
3R Petroleum Óleo e Gás S.A
SA:RRRP3
|
$625.31 Million |
|
Chow Tai Seng Jewellery Co Ltd
SHE:002867
|
$625.45 Million |
|
Nickel Mines Limited
PINK:NICMF
|
$625.69 Million |
|
Global New Material International Holdings Limited
F:69Y
|
$625.83 Million |
|
He Bei Cheng De LoLo Co Ltd
SHE:000848
|
$625.20 Million |
|
Sixt SE Pfd.
LSE:0NW8
|
$625.19 Million |
|
Stagwell Inc
NASDAQ:STGW
|
$625.11 Million |
|
Guardian Capital Group Ltd. Cl.A Nv (GCG-A.TO
TO:GCG-A
|
$625.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Balance Medical Technology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,194,613,169 to 1,252,598,226, a change of 57,985,057 (4.9%).
- Net income of 146,330,148 contributed positively to equity growth.
- Dividend payments of 109,263,392 reduced retained earnings.
- Other factors increased equity by 20,918,301.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥146.33 Million | +11.68% |
| Dividends Paid | CN¥109.26 Million | -8.72% |
| Other Changes | CN¥20.92 Million | +1.67% |
| Total Change | CN¥- | 4.85% |
Book Value vs Market Value Analysis
This analysis compares Beijing Balance Medical Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 54.49x to 11.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.86 | CN¥101.39 | x |
| 2018-12-31 | CN¥2.73 | CN¥101.39 | x |
| 2019-12-31 | CN¥7.98 | CN¥101.39 | x |
| 2020-12-31 | CN¥6.23 | CN¥101.39 | x |
| 2021-12-31 | CN¥7.33 | CN¥101.39 | x |
| 2022-12-31 | CN¥8.12 | CN¥101.39 | x |
| 2023-12-31 | CN¥8.75 | CN¥101.39 | x |
| 2024-12-31 | CN¥9.12 | CN¥101.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Balance Medical Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.68%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.16%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.14x
- Recent ROE (11.68%) is below the historical average (14.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 33.18% | 39.73% | 0.64x | 1.31x | CN¥21.78 Million |
| 2017 | 31.50% | 45.70% | 0.63x | 1.09x | CN¥28.81 Million |
| 2018 | 16.99% | 30.19% | 0.53x | 1.07x | CN¥13.74 Million |
| 2019 | 8.24% | 43.20% | 0.19x | 1.03x | CN¥-13.48 Million |
| 2020 | 6.75% | 31.07% | 0.21x | 1.04x | CN¥-27.19 Million |
| 2021 | 5.17% | 20.33% | 0.24x | 1.04x | CN¥-47.75 Million |
| 2022 | 8.64% | 32.23% | 0.25x | 1.07x | CN¥-15.01 Million |
| 2023 | 9.64% | 31.08% | 0.28x | 1.11x | CN¥-4.25 Million |
| 2024 | 11.68% | 29.16% | 0.35x | 1.14x | CN¥21.07 Million |
Industry Comparison
This section compares Beijing Balance Medical Technology Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Balance Medical Technology Co Ltd (688198) | CN¥1.21 Billion | 33.18% | 0.20x | $625.31 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |